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Abstract
Staging systems are key to predict the prognosis of patients with cancer, to stratify the patients according to prognostic
variables in the setting of clinical trials, to allow the exchange of information among researchers, and finally to guide the
therapeutic approach. The current knowledge of the disease, however, prevents recommendation of a staging system that can
be used world-wide. The conventional staging systems for hepatocellular carcinoma (HCC), such as the Okuda stage or the
TNM stage have shown important limitations in classifying patients. Several new systems have been proposed recently, and
only three of them have been validated at this point. The BCLC staging classification links the stage of the disease to a specific
treatment strategy. The JIS score has been proposed and used in Japan, although it needs Western validation. The CLIP score
is used in patients with advanced tumors. Several reasons explain the difficulty in identifying a world-wide system. First, HCC
is a complex neoplasm inserted on a pre-neoplastic cirrhotic liver, and thus variables of both diseases leading to death should
be taken into account. Second, the disease is very heterogeneous around the world, and this reflects different underlying
epidemiological backgrounds and risk factors. Third, HCC is the sole cancer treated by transplantation in a small proportion
of patients. Fourth, only around 20% of the cases are currently treated by surgery, thus precluding the wide use of pathology-
based systems, such as TNM. Finally, the potential relevance of a molecular signature identified in terms of outcome
prediction is unknown, and further research is needed to obtain this valuable biological information that may aid in classifying
the patients.
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resection, liver transplantation, percutaneous ablation, meta-analysis, chemoembolization, BCLC staging classification,
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Introduction
Hepatocellular carcinoma (HCC) is a major health
problem worldwide. It is the fifth most common
neoplasm in the world, with more than half million new
cases yearly [1]. The incidence of HCC rose in the last
decade. In the USA, the incidence of HCC is expected
to increase over the next two decades, equalling that
currently experienced in Japan [2]. HCC is now the
leading cause of death among cirrhotic patients [3].
Risk factors
Hepatocellular carcinoma develops in a cirrhotic liver
in 80% of cases, and this preneoplastic condition is the
strongest predisposing factor [4]. Hepatitis B virus
(HBV) infection is the main risk factor in Asia and
Africa. Chronic carriers have a 100-fold relative risk
for developing HCC, with an annual incidence rate of
2–6% in cirrhotic patients [5]. Aflatoxin B1 intake
further enhances the risk. In Western countries and
Japan, hepatitis C virus (HCV) infection is the main
risk factor, together with other causes of cirrhosis [4,6].
Around 20–30% of the estimated 170 million HCV-
infected individuals worldwide will develop cirrhosis.
Once cirrhosis is established, the annual incidence of
HCC is 3–5%, and one-third of these individuals will
develop an HCC over their lifetime [4].
Natural history
The natural history of this neoplasm is not completely
known. First, there are no data regarding the timescale
of the whole hepatocarcinogenetic process, which
evolves from the onset of the neoplasm until the time in
which it is diagnosed in the setting of surveillance
programmes. Second, early diagnosis of HCC still
relies on pathological data rather than molecular data,
and thus the accuracy of differentiating premalignant
lesions and early neoplasm is still ill defined. Finally,
once diagnosis is established, the prognosis of patients
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will vary according to the evolutionary stage at which
the neoplasm is diagnosed and the treatment received.
Survival of HCC patients has improved because of
the advancement of the time of diagnosis and the
increase in therapeutic efficacy. The prognosis of HCC
was dismal two decades ago [7]. Nowadays, however,
40% of HCC patients may receive curative treatments
[4,8]. These treatments are assumed to improve the
natural history of the disease. The best survival
outcome without treatment is 65% at 3 years for Child-
Pugh class A patients with single tumors [9], whereas
after radical therapies survival reaches 70% at 5 years
[4,8]. The natural course of advanced stage HCC is
better known. The 1- and 2-year survival rates of
untreated patients within 25 RCTs were 10–72% and
8–50%, respectively [10]. Overall, two groups of
patients with nonsurgical HCC have been identified:
patients at the intermediate stage (asymptomatic
tumors) show a 3-year survival rate of 50%, compared
with 8% of patients at the advanced stages [11].
Patients at terminal stages survive56 months [7].
The process of carcinogenesis
The molecular pathogenesis of HCC is complex
[12,13]. The most accepted hypothesis describes a
step-by-step process through which external stimuli
induce genetic alterations in mature hepatocytes lead-
ing to cell death and cellular proliferation (regener-
ation). In the progression of chronic inflammation to
fibrosis and cirrhosis, the up-regulation of mitogenic
pathways leads to the production of monoclonal
populations. These populations harbor dysplastic
hepatocytes as a result of altered gene expression,
telomerase erosions and even chromosome aber-
rations. This process may last 10–30 years [13]. At this
point, proliferation may be detected in isolated groups
of cells, resulting in foci of small cell dysplasia or, more
frequently, surrounded by a fibrotic ring resulting in
low-grade dysplastic nodules (LGDN) or high-grade
dysplastic nodules (HGDN) [14]. These are the major
preneoplastic entities, although HCC may also arise
from isolated small dysplastic cells, nonconforming
clear hepatic nodules, or even from progenitor cells,
which may develop mixed tumors. HGDN are
currently considered truly preneoplastic lesions, and
may develop into malignant tumors in 30% of cases
over a period of 1–5 years [15,16].
Diagnosis and prognosis of early HCC
The panel of experts on HCC of the European Asso-
ciation for the Study of the Liver (EASL) has recently
proposed diagnostic criteria for HCC that rely either on
conventional histologic characteristics or on nonin-
vasive criteria [17]. Nodules 52 cm in size should
be diagnosed by means of conventional pathological
criteria. Accuracy of fine-needle biopsy directly
depends on the size of the nodule, and ranges between
50% and 70% in small HCC of 52 cm in diameter
[19]. If nodules are 51 cm, only half of them will
correspond to HCC, and it is almost impossible to
correctly diagnose it with the current diagnostic tools.
Differentiation of early well-differentiated HCC from
preneoplastic lesions is a histopathologic challenge,
and molecular markers are awaited in this setting
[14,18]. Conversely, for nodules42 cm in the setting
of liver cirrhosis, HCC may be confidently diagnosed
by the coincidental findings of two imaging techniques
(ultrasonography, spiral CT or magnetic resonance
imaging) showing arterial hypervascularization, or by a
single positive imaging technique associated with alfa-
fetoprotein (AFP)4400 ng/ml [17].
Survival of patients with early HCC in referral liver
units may achieve 50–70% at 5 years after resection,
liver transplantation or percutaneous treatments [4,8].
In these cases, it is assumed that therapies actively
modify the natural course of the disease. These
outcomes are the result of applying the so-called
treatment-dependent variables in the selection of
candidates. In summary, these variables are single
tumors with a very well preserved liver function (no
portal hypertension, normal bilirubin) for resection,
single tumors45 cm or three nodules43 cm for liver
transplantation, and single tumors 43 cm in Child-
Pugh A patients for percutaneous treatments [4,20].
Percutaneous treatments provide good results, but are
unable to match the outcomes achieved with surgery
[20].
Recurrence is the major drawback of potentially
curative treatments. This is due to the fact that cancer
invasion and dissemination may occur in some tumors
52 cm, although others behave as the carcinoma-in-
situ entity [18]. Kojiro et al. analysed 106 resected
HCC42 cm and distinguished the so-called indistinct
type (mean size 12 mm) without local invasiveness,
from the distinct nodular type (mean size 16 mm) that
showed local invasiveness. In the latter type, local
metastases surrounding the nodule were found in 10%
of cases, and microscopic portal invasion in up to 25%.
The metastatic potential of the so-called ‘early HCC’
has been confirmed by gene expression assessment
through microarrays [21].
Intermediate-advanced HCC
Prognosis of HCC was assumed to be poor when
radical treatments were not feasible. This assumption
was based on data reported in studies describing series
of untreated HCC patients diagnosed at different
evolutionary stages, the median survival figures being
51 year [7]. These figures have also been recently
reproduced when analysing survival estimates gathered
from population-based cancer registries [22].
However, most of the patients were recruited retro-
spectively410 years ago, when regular screening was
uncommon, the imaging techniques were less accurate,
and the medical management was less effective than
nowadays. Thus, the outcome of untreated HCC has
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dramatically changed. Nowadays, the natural history
of HCC at intermediate-advanced stages can be
assessed with recent data obtained from patients
randomized to the untreated arm in the setting of
randomized controlled trials (RCTs). More than 20
RCTs have been published, including an untreated
arm of conservative management [10]. The 1- and 2-
year control survival rates in these trials were 10–72%
and 8–50%, respectively. The wide disparity of these
figures reflects the heterogeneity of the population
considered as merely with ‘unresectable HCC’, that
were suitable for other therapies in the setting of RCT.
The completion of two RCTs including a ‘no treat-
ment’ arm allowed us to recruit a cohort of 102
untreated HCC patients, who had been prospectively
followed [23]. Their survival was 54%, 40% and 28%,
at 1, 2 and 3 years, respectively, and the best predictors
of survival were the presence of cancer-related symp-
toms (Performance Status Test (PST)=1–2 or
constitutional syndrome) and the identification of an
invasive pattern evidenced by the presence of vascular
invasion or extrahepatic spread. Thereby, two
subgroups with a markedly different life expectancy
can be identified among patients in an intermediate
evolutionary stage. Patients in a truly intermediate
stage (asymptomatic patients without a tumoral in-
vasive pattern) showed a 1-, 2-, and 3-year survival rate
of 80%, 65%, and 50%, respectively, compared with
those patients at an advanced stage (at least one
adverse prognostic factor), their corresponding values
being 29%, 16%, and 8%, respectively [23].
End-stage HCC
Patients with end-stage disease are characterized by
presenting Okuda stage III, or Performance Status of
3–4, that reflects a severe tumor-related disability.
Similarly, advanced tumors in Child-Pugh C patients
also account for a very poor prognosis. We have
recently reported a 5% 6-month survival rate in Child-
Pugh C patients presenting with spontaneous bacterial
peritonitis and advanced tumors [24].
Staging systems in HCC
Cancer staging should serve to select the appropriate
primary and adjuvant therapy, to estimate the prog-
nosis, and also to assist in the evaluation of the results
of treatment, and to exchange information without
ambiguity [25]. In oncology, the prognosis of patients
with solid tumors is solely related to tumor stage, and
other co-factors such as age or histologic grade are only
seldom considered. However, HCC patients constitute
a particular case, as cirrhosis underlies the neoplasm in
most individuals and thus, their outcome is related to
these two entities, which simultaneously determine the
applicability and efficacy of treatments. Accordingly,
prognostic modeling in HCC patients is highly
complex. The EASL panel of experts recommended
the consideration of four related aspects: tumor stage,
degree of liver function impairment, general condition
of the patient, and treatment efficacy [17]. Survival of
early stage patients is modified by treatment and thus,
prognostic prediction has to include treatment-related
variables. At more advanced stages, treatment might
not be identified as a relevant survival predictor and
the use of a single prognostic model for all patients
may appear adequate. Nowadays, experts in HCC
management may choose among eight different staging
systems [7,11,26–31] (Table I), none of them with
universal acceptance [26]. The variables included in
each classification are different, reflecting the hetero-
geneous methodology used, and the population used to
construct the models (Table II). Three of them –
BCLC, CLIP and JIS score – have been validated
in different cohorts of patients (Table III), whereas
other studies have not identified any superior system
[32–37]. Therefore, a consensus staging classification
for HCC is needed.
Okuda stage
The Okuda classification [7] has been widely applied in
HCC patients in the last decade. It includes parameters
related to the liver functional status – albumin, ascites,
bilirubin – and to the tumor stage – more or less than
50% of liver area involved. This classification properly
stratified patients when most of them were diagnosed
at an advanced/symptomatic stage. It is useful to
identify end-stage patients (Okuda stage III), that
should not be included in therapeutic trials to assess
the potential benefits of new therapeutic agents due to
their grim prognosis. Nowadays, however, the time of
diagnosis has been advanced and thus, this classifi-
cation is not adequate to stratify patients prior to radical
or palliative therapies, even when dividing Okuda stage
I patients into two subgroups according to tumor size.
When compared with modern staging systems, it has
been shown to have lower predictive capacity [32–36].
Table I. Staging systems in hepatocellular carcinoma.
Classification Type Stages Reference
Okuda stage System 3 Stage I, II, III 7
French Score 3 A: 0 points; 26
B: 1–5 points;
C:56 points
CLIP Score 7 0, 1, 2, 3, 4, 5, 6 27
BCLC staging Staging 5 0: Very early 11
A: Early
B: Intermediate
C: Advanced
D: End-stage
CUPI Score 3 Low risk: score41 28
Intermediate: score 2–7
High: score58
TNM staging System 3 Stage I, II, III 29
JIS Score 4 Stage I, II, III, IV 30
ER System 2 ER wild-type 31
ER variant
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French classification
The French classification [26] was constructed with
the analysis of 761 HCC patients, among which 47%
received specific treatments. This classification
combines five variables in a score system that stratifies
patients in three stages. Survival of these stages at 2
years was of 51%, 16%, and 3%, respectively, and
reflects the fact that this cohort mostly included
patients at advanced stages. A recent comparison
with other staging systems has shown that it has
limited prognostic capacity in patients with early
HCC [32].
CLIP score
The Cancer of the Liver Italian Program (CLIP) score
[27] was constructed in a retrospective study and
validated by the authors and other groups [35–37].
This score combines four variables that provide a
seven-stage classification system. It has been compared
with Okuda stage and TNM stage with better discri-
minatory power. Asian groups have reported survival
rates clearly different to the original authors, thus
compromising their external validation [35]. It is also
limited by the fact that it does not serve to select the
appropriate therapy for each patient.
BCLC staging system
The Barcelona-Clı´nic Liver Cancer (BCLC) staging
system [4,8,11] was constructed on the basis of the
results obtained in the setting of several cohort studies
and RCTs by the Barcelona group. This proposal is not
a scoring system as it derives from the identification of
independent prognostic factors in the setting of several
studies, conforming a staging classification. This clas-
sification uses variables related to tumor stage, liver
functional status, physical status, and cancer-related
symptoms, and links the four stages described with a
treatment algorithm (Figure 1). In brief, patients at
stage 0 with very early HCC are optimal candidates for
resection. Patients at stage A with early HCC are
candidates for radical therapies (resection, liver trans-
plantation or percutaneous treatments). Patients at
stage B with intermediate HCC may benefit from
chemoembolization. Patients at stage C with advanced
HCC may receive new agents in the setting of RCT,
Table II. Prognostic variables used in the staging systems in hepatocellular carcinoma.
Variables
Classification Tumor stage Liver function Health status
Okuda stage [7] 50% liver involvement Bilirubin –
Albumin
Ascites
French [26] Portal invasion Bilirubin Karnofsky
AFP Alkaline phosphatase
CLIP [27] Portal invasion Child-Pugh –
5/450% liver involvement
AFP
BCLC [4,11] Portal invasion Child-Pugh PST
Metastases Portal hypertension
Morphology Bilirubin.
Okuda
CUPI [28] TNM Ascites Symptoms
AFP Bilirubin
Alkaline phosphatase
TNM [29] Morphology Fibrosis –
Vascular invasion
Metastases
JIS score [30] TNM Child-Pugh –
ER [31] Estrogen receptor – –
Table III. Comparison of staging systems for HCC.
Authors Journal Year/Ref Country Comparison Best Conclusion
Cillo et al. J Hepatol 2004 [32] Italy 5 systems BCLC Validation BCLC
Villa et al. J Clin Oncol 2003 [31] Italy 5 systems ER Proposal ER
Rabe et al. Eur J Gastroenterol Hepatol 2003 [33] Germany 5 systems None –
Leung et al. Cancer 2002 [28] China 4 systems CUPI Proposal CUPI
Giannini et al. J Intern Med 2004 [34] Italy 4 systems None –
Ueno et al. Hepatology 2002 [35] Japan 3 systems CLIP Validation CLIP
Farinati et al. Cancer 2000 [36] Italy 3 systems CLIP Validation CLIP
Levy and Sherman Gut 2002 [37] Canada 3 systems CLIP Validation CLIP
Kudo et al. J Gastroenterol 2003 [30] Japan 2 systems JIS Proposal JIS score
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and patients at stage D with end-stage disease will
receive symptomatic treatment.
It has been suggested that this classification is best
suited for treatment guidance, and particularly to select
early stage patients who could benefit from curative
therapies [38]. In that sense, it has recently been vali-
dated as the best staging system in a cohort of patients
with early HCC [32].
CUPI score
Investigators in Hong Kong described a staging system
analysing their experience in 926 patients, most of
them with HBV-related cirrhosis [28]. The Chinese
University Prognostic Index (CUPI) considers six
predictive variables, and divides patients into three
stages. The authors estimate that this classification has
better estimation of survival than CLIP score and
Okuda stage, although its discriminatory power in early
stages is questionable, as the best 1-year survival was
around 50%.
TNM stage
The conventional TNM system, which only contains
variables related to tumor stage, has been mostly tested
in the surgical setting, and showed poor prognostic
prediction in HCC patients undergoing either re-
section [39] or transplantation [40]. Based on the
results of a series of 557 patients who underwent re-
section [29], a recent modification has been proposed,
including tumor stage and presence of fibrosis. The
new four-stage system may improve the stratification of
resected tumors, even though it is controversial
whether they will apply to nonsurgical patients. It has
been endorsed by the American Joint Committee on
Cancer (AJCC).
JIS staging
The Japan Integrated Staging (JIS) is a new score
system that includes two previous classifications: the
TNM endorsed by the Union Internationale Contre le
Cancer (UICC) [41], mostly applied in Japan, and the
Child-Pugh classification. It lacks external validation
in Western countries.
Critical appraisal of HCC classifications and
future prospects
There is no doubt that the classical staging systems
have already been improved. The Okuda staging and
the Child-Pugh classification might be used as a part of
any new clinical staging system, but should no longer
be used alone. Attempts to improve the classification
and prognosis prediction of HCC are still evolving, and
there is no agreement on the best staging that can be
recommended worldwide [17]. The heterogeneous
survival figures described for the best stages (3-year
survival from 80% [11] to 25% [28]) reflect that some
studies include mostly advanced cases with a minor
number of effectively treated patients. In these studies,
Figure 1. Barcelona-Clinic Liver Cancer (BCLC) staging classification and treatment schedule. (Adapted from Llovet JM et al.,
Lancet 2003 [4].)
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treatment-related variables might not be identified as a
relevant survival predictor and the use of the same set
of variables for all patients may appear adequate.
Conversely they face the same difficulty in early cases,
as prognostic modeling for early HCC has specific
requirements [26–28]. The CUPI, CLIP, and French
staging systems have been constructed with patients at
advanced stages. They use rough descriptions of tumor
stage that are not in accordance with the predictive
value of tumor size and multicentricity. For instance,
the CLIP score classifies the tumor burden as above/
below 50% of liver involvement, thus making it
impossible by definition to identify patients at early
stages. The new TNM according with the AJCC has
only internal validation, and is based on series of
patients undergoing resection [29], as is the case with
the seminal paper proposing JIS classification [30].
Pathologic information is needed in all cases, this
representing a limitation for wide clinical use.
The BCLC staging system has been validated by a
surgically oriented European group [32]. This study
includes the widest comparison among staging
systems, in comparison with other retrospective studies
in which the limited collection of data impairs the
ability to test all the systems available. The BCLC
staging system may discriminate patients at early
stages, and guide the treatment strategy. More
recently, new systems have appeared, suggesting a
stronger discriminatory power when compared with
published ones [31]. Even some societies have
endorsed one of the systems [42], with controversial
acceptance [43,44].
Our current level of knowledge prevents recom-
mendation of a staging system to be used worldwide.
HCC is a complex neoplasm, in most cases on a
background of a preneoplastic damaged liver. Both
diseases may lead to death. In addition, unlike breast
cancer [45] and lymphoma [46], no clear biologic/
genetic markers have been shown to have prognostic
value in HCC. In that sense, several human malignant
tumors have recently been classified with respect to
their prognostic outcome or response to treatment
according to gene expression profile identified through
micro-array technology. Investigators have developed
gene expression-based classifications for breast cancer,
non-Hodgkin’s B-cell lymphoma, leukemia, lung
carcinoma, prostate cancer, bladder cancer, and
melanoma. Thus, molecular markers are needed in
HCC. However, to be clinically useful, the molecular
classification should be incorporated into a staging
scheme, which effectively separates patients into
groups with homogeneous prognosis and response to
treatment, and thus serves to aid in the selection of
appropriate therapy. The potential relevance of a
molecular signature identified in terms of outcome
prediction should ultimately be tested in large cohorts
of patients and analysed together with well-known
clinical variables, as has been done recently for breast
cancer [47].
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